JPH0390030A - Calcium preparation - Google Patents

Calcium preparation

Info

Publication number
JPH0390030A
JPH0390030A JP1226216A JP22621689A JPH0390030A JP H0390030 A JPH0390030 A JP H0390030A JP 1226216 A JP1226216 A JP 1226216A JP 22621689 A JP22621689 A JP 22621689A JP H0390030 A JPH0390030 A JP H0390030A
Authority
JP
Japan
Prior art keywords
calcium
carbonate
xylitol
salt
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1226216A
Other languages
Japanese (ja)
Other versions
JP2616822B2 (en
Inventor
Masami Moroi
諸井 政己
Kimie Oominato
大湊 希己江
Toshio Yokoyama
俊夫 横山
Akira Iwasa
岩佐 曜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SSP Co Ltd
Original Assignee
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd filed Critical SSP Co Ltd
Priority to JP1226216A priority Critical patent/JP2616822B2/en
Priority to CA002023493A priority patent/CA2023493C/en
Priority to KR1019900013153A priority patent/KR100187951B1/en
Priority to DE69012932T priority patent/DE69012932T2/en
Priority to EP90116398A priority patent/EP0415326B1/en
Publication of JPH0390030A publication Critical patent/JPH0390030A/en
Priority to US07/806,791 priority patent/US5204087A/en
Application granted granted Critical
Publication of JP2616822B2 publication Critical patent/JP2616822B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

PURPOSE:To provide a calcium agent having good taste and oral administration touch, readily ingested and suitable for long period continuous administration by containing a calcium salt, xylitol, an organic acid and a carbonate salt. CONSTITUTION:A calcium agent contains a calcium salt (any one of organic and inorganic calcium salts can be used), 5-90wt.%, especially 40-70wt.%, of xylitol as an excipient, 0.5-50wt.%, particularly 1-10wt.%, of an organic acid (e.g. ascorbic acid or succinic acid) and 0.5-50wt.%, especially 1-10wt.%, of a carbonate salt. When calcium carbonate is used as the calcium salt, the calcium agent does not require any other carbonate salt and contains 5-80wt.%, particularly 30-60wt.%, of the calcium carbonate. The agent has a good oral administration touch due to an oral stimulating touch caused by the foaming of the agent, due to the improvement of the dissolution of the calcium caused by the generated carbon dioxide gas and to the cooling touch of the xylitol.

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は、服用感の良いカルシウム製剤に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a calcium preparation that is comfortable to take.

〔従来の技術] 国民栄養調査によると、今日、各栄養素摂取量はいずれ
も平均所要量を上回っているのに、カルシウムについて
は1日600ngの所要量に対して553I1gの摂取
量と、低い値に留っている。そのためカルシウム欠乏症
(骨病変)の危険が日本人全体にあるといってよい。特
に1日の所要量が多い妊産婦、授乳婦、成長期の子供や
、カルシウムの吸収力の弱い老人などは、カルシウム欠
乏症の予防または治療のため、カルシウム製剤の常用が
必要となる。
[Prior art] According to the National Nutrition Survey, today the intake of each nutrient exceeds the average required amount, but the intake of calcium is low at 553I1g per day compared to the required amount of 600ng. It remains in Therefore, it can be said that all Japanese people are at risk of calcium deficiency (bone lesions). In particular, pregnant women, nursing mothers, growing children, and elderly people who require a large amount of calcium per day, such as the elderly who have a weak ability to absorb calcium, require regular use of calcium preparations to prevent or treat calcium deficiency.

[発明が解決しようとする課題] かかるカルシウム製剤は、上記のように長期連続服用を
要するため、服用感の良い剤型であることが望ましい。
[Problems to be Solved by the Invention] Since such calcium preparations require continuous administration over a long period of time as described above, it is desirable that they be in a dosage form that is comfortable to take.

しかし、カルシウム含量の多い無機系カルシウムを用い
ると、服用すべき製剤量は少なくなるが、無機系カルシ
ウムが刺激性であったり溶解性が悪いため舌ざわりの悪
い製剤となる。
However, when inorganic calcium with a high calcium content is used, the amount of the preparation to be taken is reduced, but the inorganic calcium is irritating and has poor solubility, resulting in a preparation with a bad texture.

また、有機系カルシウムを用いると、舌ざわりは良くな
るが、カルシウム含量が少ないため服用すベき製剤量が
多くなり、長期連続服用は困難となる。そこで、無機系
カルシウムと有機系カルシウムの併用により、服用感を
向上すべく努力はされているが、満足し得る効果は得ら
れていない。
Furthermore, when organic calcium is used, the texture becomes better on the tongue, but since the calcium content is low, the amount of the preparation that must be taken increases, making it difficult to take it continuously for a long period of time. Therefore, efforts have been made to improve the feeling of taking the drug by using a combination of inorganic calcium and organic calcium, but no satisfactory effect has been achieved.

従って、本発明は味及び服用感が良く、摂取が容易で長
期連続服用に適したカルシウム製剤を提供することを目
的とする。
Therefore, an object of the present invention is to provide a calcium preparation that has good taste and feeling, is easy to take, and is suitable for long-term continuous administration.

[課題を解決するための手段] かかる実情において、本発明者らは鋭意研究を行なった
結果、賦形剤としてキシリトールを用いた発泡性の製剤
が上記課題を解決し得るものであることを見出し、本発
明を完成した。
[Means for Solving the Problems] Under these circumstances, the present inventors conducted intensive research and found that an effervescent formulation using xylitol as an excipient can solve the above problems. , completed the invention.

すなわち本発明は、カルシウム塩、キシリトール、有機
酸及び炭酸塩を含有することを特徴とするカルシウム製
剤、並びに炭酸カルシウム、キシリトール及び有機酸を
含有することを特徴とするカルシウム製剤を提供するも
のである。
That is, the present invention provides a calcium preparation characterized by containing a calcium salt, xylitol, an organic acid, and a carbonate, and a calcium preparation characterized by containing calcium carbonate, xylitol, and an organic acid. .

本発明において使用し得るカルシウム塩としては、無機
系カルシウムとして塩化カルシウム、リン酸水素カルシ
ウム、沈降炭酸カルシウム、ボレー等が、有機系カルシ
ウムとしてグルコン酸カルシウム、乳酸カルシウム、ア
スパラギン酸カルシウム、グリセロリン酸カルシウム等
が挙げられる。
Examples of calcium salts that can be used in the present invention include inorganic calcium such as calcium chloride, calcium hydrogen phosphate, precipitated calcium carbonate, and boley, and organic calcium such as calcium gluconate, calcium lactate, calcium aspartate, and calcium glycerophosphate. Can be mentioned.

これらは単独で、または2種以上を組み合わせて使用す
ることができる。
These can be used alone or in combination of two or more.

本発明において、キシリトールは賦形剤として使用され
、その使用量は本発明カルシウム製剤の5〜90重量%
、特に40〜70重量%が好ましい。
In the present invention, xylitol is used as an excipient, and the amount used is 5 to 90% by weight of the calcium preparation of the present invention.
, particularly preferably 40 to 70% by weight.

また、本発明において使用し得る有機酸としては、アス
コルビン酸、コハク酸、酒石酸、クエン酸、リンゴ酸、
フマル酸、乳酸、グルコン酸等が挙げられる。これらは
単独で、または2種以上を組み合わせて使用することが
できる。有機酸の使用量は本発明カルシウム製剤に対し
て0.5〜50重量%、特に1〜10重量%が好ましい
In addition, organic acids that can be used in the present invention include ascorbic acid, succinic acid, tartaric acid, citric acid, malic acid,
Examples include fumaric acid, lactic acid, and gluconic acid. These can be used alone or in combination of two or more. The amount of organic acid used is preferably 0.5 to 50% by weight, particularly 1 to 10% by weight, based on the calcium preparation of the present invention.

更に、本発明において使用し得る炭酸塩としては、炭酸
水素ナトリウム、炭酸カルシウム、炭酸ナトリウム、炭
酸カリウム、炭酸アンモニウム、炭酸マグネシウム等が
挙げられる。これらは単独で、または2種以上を組み合
わせて使用することができる。炭酸塩の使用量は本発明
カルシウム製剤に対して0.5〜50重量%、特に1〜
10重量%が好ましい。なお、カルシウム塩として炭酸
カルシウムを使用する場合は、このもの自体が炭酸塩で
あるので、更に他の炭酸塩を使用する必要はない。
Further, carbonates that can be used in the present invention include sodium hydrogen carbonate, calcium carbonate, sodium carbonate, potassium carbonate, ammonium carbonate, magnesium carbonate, and the like. These can be used alone or in combination of two or more. The amount of carbonate used is 0.5 to 50% by weight, especially 1 to 50% by weight, based on the calcium preparation of the present invention.
10% by weight is preferred. Note that when calcium carbonate is used as the calcium salt, since this itself is a carbonate, there is no need to further use another carbonate.

この場合、炭酸カルシウムの使用量は、本発明カルシウ
ム製剤に対して5〜80重量%、特に30〜60重量%
が好ましい。
In this case, the amount of calcium carbonate used is 5 to 80% by weight, particularly 30 to 60% by weight, based on the calcium preparation of the present invention.
is preferred.

本発明のカルシウム製剤は種々の剤型とすることができ
るが、摂取の容易性を考慮すると、顆粒剤、細粒剤、錠
剤等の剤型とするのが好ましい。
The calcium preparation of the present invention can be made into various dosage forms, but in consideration of ease of ingestion, dosage forms such as granules, fine granules, and tablets are preferred.

本発明のカルシウム製剤には、更に必要に応じてその他
の栄養成分または一般に用いられる賦形剤、結合剤、崩
壊剤、滑沢剤等をその剤型により添加してもよい。賦形
剤としては、デンプン、結晶セルロース、マンニトール
、乳糖、白糖、ソルビトール、デキストリン、軽質無水
ケイ酸等が挙げられる。結合剤としては、セルロース誘
導体、合成高分子化合物等が挙げられ、特にヒドロキシ
プロピルセルロースが好ましい。また、本発明カルシウ
ム製剤の成分の一部または全部を該結合剤でコーティン
グすることが好ましい。崩壊剤としては、デンプン、結
晶セルロース、カルボキシメチルセルロースカルシウム
等が挙げられる。また、錠剤とする場合の滑沢剤として
は、タルク、ステアリン酸、ステアリン酸マグネシウム
、パラフィン等が挙げられる。
If necessary, other nutritional ingredients or commonly used excipients, binders, disintegrants, lubricants, etc. may be added to the calcium preparation of the present invention depending on its dosage form. Excipients include starch, crystalline cellulose, mannitol, lactose, sucrose, sorbitol, dextrin, light silicic anhydride, and the like. Examples of the binder include cellulose derivatives and synthetic polymer compounds, with hydroxypropyl cellulose being particularly preferred. Moreover, it is preferable to coat some or all of the components of the calcium preparation of the present invention with the binder. Examples of the disintegrant include starch, crystalline cellulose, carboxymethylcellulose calcium, and the like. In addition, examples of lubricants for tablets include talc, stearic acid, magnesium stearate, paraffin, and the like.

本発明のカルシウム製剤は、例えば次のようにして製造
される。すなわち、カルシウム塩に、キシリトール、有
機酸及び炭酸塩のほか、結合剤、崩壊剤等を加え、常法
により造粒または整粒することにより顆粒剤または細粒
剤が得られる。また、滑沢剤を添加して常法により製錠
することにより錠剤が得られる。
The calcium preparation of the present invention is manufactured, for example, as follows. That is, granules or fine granules can be obtained by adding xylitol, an organic acid, a carbonate, a binder, a disintegrant, etc. to a calcium salt, and granulating or sizing the mixture by a conventional method. Further, tablets can be obtained by adding a lubricant and tabletting by a conventional method.

[作用及び発明の効果] 本発明のカルシウム製剤は叙上のごとく構成されている
ので、服用時、発泡による日中での刺激感、発生する炭
酸ガスによるカルシウムの溶解性向上及びキシリトール
の冷涼感により、服用感がよく、摂取が容易であり、特
に長期連用に適している。
[Actions and Effects of the Invention] The calcium preparation of the present invention is configured as described above, so that when taken, the foaming causes a feeling of irritation during the day, the carbon dioxide generated improves the solubility of calcium, and the xylitol provides a cooling sensation. Therefore, it has a good feel and is easy to take, and is particularly suitable for long-term use.

[実施例] 以下、実施例を挙げて更に詳細に説明するが、本発明は
これらに限定されるものではない。
[Examples] Hereinafter, the present invention will be explained in more detail by giving examples, but the present invention is not limited thereto.

実施例1 沈降炭酸カルシウム1500g、キシリトール2863
.2g及びヒドロキシプロピルセルロース220gを均
一に混合し、エタノールを加えて練合した後、50℃で
乾燥し篩分けして、12号篩通過、42号篩残のものを
得た。これに、流動相コーティング装置を用いて酒石酸
192gにヒドロキシプロピルセルロース20gをコー
ティングしたもの及び香料4.8gを添加し、均一に混
合して顆粒剤を得た。
Example 1 Precipitated calcium carbonate 1500g, xylitol 2863
.. 2 g of hydroxypropyl cellulose and 220 g of hydroxypropyl cellulose were uniformly mixed, ethanol was added and kneaded, and then dried at 50° C. and sieved to obtain a product that passed through a No. 12 sieve and remained on a No. 42 sieve. To this, 192 g of tartaric acid coated with 20 g of hydroxypropyl cellulose and 4.8 g of fragrance were added using a fluid phase coating device and mixed uniformly to obtain granules.

用法・容量:1回1包(1,6g) 1日3回服用実施
例2 沈降炭酸カルシウム1500g、塩酸リジン125g。
Usage/Capacity: 1 packet (1.6 g) at a time, taken 3 times a day Example 2 Precipitated calcium carbonate 1500 g, lysine hydrochloride 125 g.

アミノエチルスルホン酸75g1エルゴカルシフエロー
ル10■、キシリトール2663 、2g、ヒドロキシ
プロピルセルロース240g及び酒石酸192gを均一
に混合し、エタノールを加えて練合した後、50℃で乾
燥し篩分けして30号篩通過、200号篩残のものを得
た。これに香料4.8gを添加して細粒剤を得た。
75g of aminoethylsulfonic acid, 10g of ergocalciferol, 2g of xylitol 2663, 240g of hydroxypropylcellulose and 192g of tartaric acid were mixed uniformly, ethanol was added and kneaded, then dried at 50°C and sieved through a No. 30 sieve. It passed through the sieve, and a No. 200 sieve residue was obtained. 4.8 g of fragrance was added to this to obtain fine granules.

用法・容量:1回1包(1,6g) 1日3回服用実施
例3 リン酸水素カルシウム2576g、キシリトール140
3.2g及びヒドロキシプロピルセルロース240gを
均一に混合し、エタノールを加えて練合した後、50℃
で乾燥し20号篩過した。これに酒石酸、炭酸水素ナト
リウム及びステアリン酸マグネシウム各192g並びに
香料4.8gを添加し、菊水社製ロータリー打錠機を用
いて製錠し、直径15關重さ1.6gのチュアブル錠を
得た。
Usage/Capacity: 1 packet (1.6 g) at a time, taken 3 times a day Example 3 Calcium hydrogen phosphate 2576 g, xylitol 140
After uniformly mixing 3.2 g and 240 g of hydroxypropyl cellulose, adding ethanol and kneading, the mixture was heated to 50°C.
It was dried and passed through a No. 20 sieve. To this, 192 g each of tartaric acid, sodium hydrogen carbonate, and magnesium stearate, and 4.8 g of fragrance were added, and tablets were made using a rotary tablet press manufactured by Kikusui Co., Ltd. to obtain chewable tablets with a diameter of 15 mm and a weight of 1.6 g. .

用法・容量=1回1錠1日3回、日中で溶かすか、また
は噛み砕いて服用 実施例4 リン酸水素カルシウム1850g、グルコン酸カルシウ
ム1850g、キシリトール279.2g及びヒドロキ
シプロピルセルロース240gを均一に混合し、エタノ
ールを加えて練合した後、50℃で乾燥し20号篩過し
た。これに酒石酸、炭酸水素ナトリウム及びステアリン
酸マグネシウム各192g並びに香料4.8gを添加し
、菊水社製ロータリー打錠機を用いて製錠し、直径15
mn重さ1.6gのチュアブル錠を得た。
Dosage/Capacity: 1 tablet at a time, 3 times a day, dissolve or chew during the day. Example 4: 1850 g of calcium hydrogen phosphate, 1850 g of calcium gluconate, 279.2 g of xylitol, and 240 g of hydroxypropyl cellulose are uniformly mixed together. After adding ethanol and kneading, the mixture was dried at 50°C and passed through a No. 20 sieve. To this was added 192 g each of tartaric acid, sodium hydrogen carbonate, magnesium stearate, and 4.8 g of fragrance, and the tablets were made using a rotary tablet machine manufactured by Kikusui Co., Ltd., with a diameter of 15 mm.
Chewable tablets weighing 1.6 g were obtained.

用法・容量:1回1錠1日3回、日中で溶かすか、また
は噛み砕いて服用 比較例1 沈降炭酸カルシウム1500g、精製白糖3055 、
2g及びヒドロキシプロピルセルロース240gを均一
に混合し、エタノールを加えて練合した後、50℃で乾
燥し篩分けして12号篩通過、42号篩残のものを得た
。これに香料4.8gを添加混合して顆粒剤を得た。
Dosage/Capacity: 1 tablet at a time, 3 times a day, dissolve or chew during the day Comparative Example 1 Precipitated calcium carbonate 1500g, refined white sugar 3055g,
2 g of hydroxypropylcellulose and 240 g of hydroxypropyl cellulose were uniformly mixed, ethanol was added and kneaded, and then dried at 50° C. and sieved to obtain a product that passed through a No. 12 sieve and remained on a No. 42 sieve. 4.8 g of fragrance was added and mixed to obtain granules.

比較例2 沈降炭酸カルシウム1500g、塩酸リジン125g。Comparative example 2 1500 g of precipitated calcium carbonate, 125 g of lysine hydrochloride.

アミノエチルスルホン酸75g1エルゴカルシフエロー
ル10mg、 D−vンニトール2855.2g及びヒ
ドロキシプロピルセルロース240gを均一に混合し、
エタノールを加えて練合した後、50℃で乾燥し篩分け
して30号篩通過、200号篩残のものを得た。これに
香料4.8gを添加して細粒剤を得た。
75 g of aminoethyl sulfonic acid, 10 mg of ergocalciferol, 2855.2 g of D-vnitol and 240 g of hydroxypropyl cellulose were uniformly mixed,
After adding ethanol and kneading, the mixture was dried at 50°C and sieved to obtain a product that passed through a No. 30 sieve and remained on a No. 200 sieve. 4.8 g of fragrance was added to this to obtain fine granules.

比較例3 リン酸水素カルシウム2576g、乳糖1787.2g
及びヒドロキシプロピルセルロース240gを均一に混
合し、エタノールを加えて練合した後、50℃で乾燥し
20号篩過した。これにステアリン酸マグネシウム19
2g及び香料4,8gを添加し、菊水社製ロータリー打
錠機を用いて製錠し、直径15 m重さ1.6gのチュ
アブル錠を得た。
Comparative Example 3 Calcium hydrogen phosphate 2576g, lactose 1787.2g
and 240 g of hydroxypropyl cellulose were uniformly mixed, ethanol was added and kneaded, and the mixture was dried at 50° C. and passed through a No. 20 sieve. This includes magnesium stearate 19
2 g and 4.8 g of fragrance were added, and tablets were made using a rotary tablet press manufactured by Kikusui Co., Ltd. to obtain chewable tablets with a diameter of 15 m and a weight of 1.6 g.

比較例4 リン酸水素カルシウム1850g、グルコン酸カルシウ
ム1850g、精製白糖663.2g及びヒドロキシプ
ロピルセルロース240gを均一に混合し、エタノール
を加えて練合した後、50℃で乾燥し20号篩過した。
Comparative Example 4 1850 g of calcium hydrogen phosphate, 1850 g of calcium gluconate, 663.2 g of refined white sugar and 240 g of hydroxypropyl cellulose were uniformly mixed, ethanol was added and kneaded, then dried at 50° C. and passed through a No. 20 sieve.

これにステアリン酸マグネシウム192g及び香料4.
8gを添加し、菊水社製ロータリー打錠機を用いて製錠
し、直径15圓重さ1.6gのチュアブル錠を得た。
Add to this 192g of magnesium stearate and 4.
8 g was added and tablets were made using a rotary tablet press manufactured by Kikusuisha Co., Ltd. to obtain chewable tablets with a diameter of 15 circles and a weight of 1.6 g.

試験例1 実施例1〜4及び比較例1〜4で得たカルシウム製剤の
服用感を6名のパネラ−により比較した。
Test Example 1 Six panelists compared the feeling of taking the calcium preparations obtained in Examples 1 to 4 and Comparative Examples 1 to 4.

実施例1〜4の本発明カルシウム製剤はいずれも味がよ
く、粉っぽくなく、口当たりが良かったのに対し、比較
例1〜4のカルシウム製剤はいずれも粉っぽく、服用感
が悪かった。
The calcium preparations of the present invention in Examples 1 to 4 all had good taste, were not powdery, and had a good texture, whereas the calcium preparations in Comparative Examples 1 to 4 were all powdery and had a poor feeling when taking. .

以上that's all

Claims (5)

【特許請求の範囲】[Claims] (1)カルシウム塩、キシリトール、有機酸及び炭酸塩
を含有することを特徴とするカルシウム製剤。
(1) A calcium preparation characterized by containing a calcium salt, xylitol, an organic acid, and a carbonate.
(2)有機酸及び炭酸塩の含有量が、それぞれ0.5〜
50重量%である請求項1記載のカルシウム製剤。
(2) The contents of organic acid and carbonate are each 0.5 to 0.5
The calcium preparation according to claim 1, which is 50% by weight.
(3)炭酸カルシウム、キシリトール及び有機酸を含有
することを特徴とするカルシウム製剤。
(3) A calcium preparation containing calcium carbonate, xylitol, and an organic acid.
(4)炭酸カルシウムの含有量が、5〜80重量%であ
る請求項3記載のカルシウム製剤。
(4) The calcium preparation according to claim 3, wherein the content of calcium carbonate is 5 to 80% by weight.
(5)キシリトールの含有量が、5〜90重量%である
請求項1または3記載のカルシウム製剤。
(5) The calcium preparation according to claim 1 or 3, wherein the content of xylitol is 5 to 90% by weight.
JP1226216A 1989-08-31 1989-08-31 Calcium preparation Expired - Lifetime JP2616822B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP1226216A JP2616822B2 (en) 1989-08-31 1989-08-31 Calcium preparation
CA002023493A CA2023493C (en) 1989-08-31 1990-08-17 Composition for foaming preparation
KR1019900013153A KR100187951B1 (en) 1989-08-31 1990-08-24 Composition for foaming preparation
DE69012932T DE69012932T2 (en) 1989-08-31 1990-08-27 Preparation for foaming preparation.
EP90116398A EP0415326B1 (en) 1989-08-31 1990-08-27 Composition for foaming preparation
US07/806,791 US5204087A (en) 1989-08-31 1991-12-12 Composition for foaming preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1226216A JP2616822B2 (en) 1989-08-31 1989-08-31 Calcium preparation

Publications (2)

Publication Number Publication Date
JPH0390030A true JPH0390030A (en) 1991-04-16
JP2616822B2 JP2616822B2 (en) 1997-06-04

Family

ID=16841716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1226216A Expired - Lifetime JP2616822B2 (en) 1989-08-31 1989-08-31 Calcium preparation

Country Status (1)

Country Link
JP (1) JP2616822B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013539768A (en) * 2010-10-13 2013-10-28 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング Phosphate binder formulation for easy administration
JP2015073611A (en) * 2013-10-07 2015-04-20 アース製薬株式会社 Aromatic

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207322A (en) * 1985-03-11 1986-09-13 Sunstar Inc Foamable solid composition containing ascorbic acid
JPS6289616A (en) * 1985-10-16 1987-04-24 Kao Corp Tablet production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207322A (en) * 1985-03-11 1986-09-13 Sunstar Inc Foamable solid composition containing ascorbic acid
JPS6289616A (en) * 1985-10-16 1987-04-24 Kao Corp Tablet production

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013539768A (en) * 2010-10-13 2013-10-28 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング Phosphate binder formulation for easy administration
JP2015073611A (en) * 2013-10-07 2015-04-20 アース製薬株式会社 Aromatic

Also Published As

Publication number Publication date
JP2616822B2 (en) 1997-06-04

Similar Documents

Publication Publication Date Title
US5753254A (en) Therapeutic agents containing thyroid hormones
KR950009090B1 (en) Pharmaceutical composition containing ibuprofen and aluminium hydroxide
JP2546068B2 (en) Preparation containing L-carnitine
KR100898970B1 (en) Particulate comprising a calcium-containing compound and a sugar alcohol
PT1660104E (en) Pharmaceutical formulation comprising lanthanum compounds
JPS63211224A (en) Water-dispersible tablet
US5432200A (en) Method for increasing urinary excretion of electrolytes
JP2016174616A (en) Disintegrable composition, and easily disintegrable compression molding
DK169605B1 (en) Magnesium additive for food, feed and pharmaceuticals
KR100187951B1 (en) Composition for foaming preparation
JP4501024B2 (en) Composition with reduced bitterness and odor of cysteines
JP2995226B2 (en) Chewable tablets containing calcium
JPH0559090B2 (en)
JPH01151515A (en) Treatment of osteoporosis and related disorder
JP5168712B2 (en) Nateglinide-containing preparation
JPH09502709A (en) Oral, water-soluble pharmaceutical composition containing estrone derivative and calcium salt
JPH0390030A (en) Calcium preparation
JP3067125B2 (en) Easy-to-take nucleated tablet-type preparation
US5204087A (en) Composition for foaming preparation
JP6554034B2 (en) Calcium agent
JPH09169651A (en) Vitamin-containing tablet and its production
CA1326040C (en) Magnesium-potassium citrate
HU211084B (en) Process for producing oral pharmaceutical composition of bone strengthening activity
JP2009137872A (en) Glucuronolactone-containing solid preparation for oral use
JP3545512B2 (en) Effervescent tablets containing crude drugs